Floatz logo

Jwcar239

B-Cell Non-Hodgkin Lymphoma

Peking University Cancer Hospital & InstitutePhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

316 Active assets in the B-Cell Non-Hodgkin Lymphoma cohort.

Asset / SponsorPhaseRating
VINDESINE
Children's Cancer Group, China
Phase 4BBB
cc-5013
Shanghai Junshi Bioscience Co., Ltd.
Phase 4BBB
Odronextamab
University of Birmingham
Phase 3BBB
METHOTREXATE
Children's Cancer Group, China
Phase 4BBB
Cytosin-Arabinosid
Children's Cancer Group, China
Phase 4BBB

View all 50 →

Same molecule, other indications

Jwcar239 is also rated in:

diffuse large B-cell lymphomaDormant
CC
Indicative ·
43 / 100
View asset →
mantle cell lymphomaDormant
CC
Indicative ·
41 / 100
View asset →
follicular lymphomaDormant
C
Indicative ·
37 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →